JP2023509966A5 - - Google Patents

Info

Publication number
JP2023509966A5
JP2023509966A5 JP2022542209A JP2022542209A JP2023509966A5 JP 2023509966 A5 JP2023509966 A5 JP 2023509966A5 JP 2022542209 A JP2022542209 A JP 2022542209A JP 2022542209 A JP2022542209 A JP 2022542209A JP 2023509966 A5 JP2023509966 A5 JP 2023509966A5
Authority
JP
Japan
Prior art keywords
sequence
composition according
dna sequence
dna
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509966A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012834 external-priority patent/WO2021142366A1/en
Publication of JP2023509966A publication Critical patent/JP2023509966A/ja
Publication of JP2023509966A5 publication Critical patent/JP2023509966A5/ja
Pending legal-status Critical Current

Links

JP2022542209A 2020-01-10 2021-01-08 腫瘍溶解性ウイルス様小胞の組成物および使用方法 Pending JP2023509966A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959435P 2020-01-10 2020-01-10
US62/959,435 2020-01-10
PCT/US2021/012834 WO2021142366A1 (en) 2020-01-10 2021-01-08 Compositions and methods of use of oncolytic virus like vesicles

Publications (2)

Publication Number Publication Date
JP2023509966A JP2023509966A (ja) 2023-03-10
JP2023509966A5 true JP2023509966A5 (cg-RX-API-DMAC7.html) 2024-01-15

Family

ID=74595378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542209A Pending JP2023509966A (ja) 2020-01-10 2021-01-08 腫瘍溶解性ウイルス様小胞の組成物および使用方法

Country Status (5)

Country Link
US (1) US12577585B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087858A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023509966A (cg-RX-API-DMAC7.html)
CN (1) CN115397838A (cg-RX-API-DMAC7.html)
WO (1) WO2021142366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性b型肝炎感染症を処置または防止するための複数抗原治療ワクチン
JP2025508866A (ja) * 2022-02-22 2025-04-10 ヴァイロ バイオ インク. 腫瘍溶解性ウイルスおよび使用方法
JP2025506732A (ja) * 2022-02-22 2025-03-13 カロジェン コーポレイション 感染症およびがんの免疫療法適用のための多用途のウイルス様小胞(vlv)プラットフォーム
CN117327709A (zh) * 2022-06-24 2024-01-02 深圳瑞吉生物科技有限公司 用于实体肿瘤的治疗性mRNA及其应用
US20260034208A1 (en) * 2022-07-26 2026-02-05 Yale University Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
IL320318A (en) * 2022-10-19 2025-06-01 Kalivir Immunotherapeutics Inc Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof
WO2024119388A1 (zh) * 2022-12-07 2024-06-13 上海鑫湾生物科技有限公司 一种用于共表达多种目的基因的构建体及其用途
CN118831091A (zh) * 2023-04-11 2024-10-25 浙江自贸区红岸基地生物科技有限公司 一种saRNA递送系统及其制备方法和应用
WO2025208054A1 (en) * 2024-03-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Recombinant rhabdovirus encoding interleukin-12 (il-12)
CN120733012B (zh) * 2024-08-20 2026-08-07 浙江大学 基于mRNA及蛋白编码的肿瘤药物、制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
FR2862982B1 (fr) 2003-12-02 2006-04-28 Genethon Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale.
AU2007342333B2 (en) * 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
GB2460265A (en) 2008-05-23 2009-11-25 Univ Dublin City Detection assembly
AU2015259470A1 (en) * 2014-05-16 2016-11-10 Yale University Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
WO2015175382A1 (en) 2014-05-16 2015-11-19 Yale University Evolution of high-titer virus-like vesicles for vaccine applications
EP3437654B1 (en) 2016-03-31 2023-09-20 Centro De Ingeniería Genética Y Biotecnología Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
CN110050062A (zh) * 2016-08-09 2019-07-23 阿尔莫哈纳德·阿尔卡亚尔 表达il12的溶瘤弹状病毒
PT3684786T (pt) 2017-09-22 2024-10-30 Centre Nat Rech Scient Glicoproteína mutante do vírus da estomatite vesicular

Similar Documents

Publication Publication Date Title
Gardner et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein
CA2410948C (en) Method for the purification of alphavirus replicon particles
JP7855208B2 (ja) 非組み込みウイルス送達系およびその関連方法
JP2022191506A5 (cg-RX-API-DMAC7.html)
CN111358953A (zh) 一种高效诱导机体体液免疫应答的疫苗载体、其制备方法及用途
CN106967685B (zh) 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
JP2023509966A (ja) 腫瘍溶解性ウイルス様小胞の組成物および使用方法
JP2023521662A5 (cg-RX-API-DMAC7.html)
Ljungberg et al. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine
CN108017717A (zh) 一种用于体外高效定向扩增的嵌合抗原受体及其应用
JP2024073653A (ja) 遺伝子改変リンパ球の製造方法
CN106459997A (zh) 用于疫苗应用的高效价病毒样囊泡的进化
CN110832072A (zh) 用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法
CN118234850A (zh) 利用微rna来下调经修饰的安卡拉痘苗病毒(mva)的细胞毒性转基因的表达
US20260069678A1 (en) Conjugate polypeptides and vaccines for inducing immune responses
Zhang et al. Virus-like vesicles based on Semliki forest virus-containing rabies virus glycoprotein make a safe and efficacious rabies vaccine candidate in a mouse model
Cervantes-Barragan et al. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity
Lundstrom Viral vector-based cancer vaccines
CN109796536B (zh) 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
JP2024542126A5 (cg-RX-API-DMAC7.html)
CN120366237A (zh) 重组溶瘤疱疹病毒及其应用
Karlsson et al. Live viral vectors: Semliki Forest virus
Gea-Mallorquí et al. DC-targeting lentivectors for cancer immunotherapy
WO2023015276A1 (en) Adenoviral vector-based vaccine for emerging viruses
Aranda et al. A quick and efficient method to generate mammalian stable cell lines based on a novel inducible alphavirus DNA/RNA layered system